Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» Positive Results from Optimer Pharmaceuticals' Second Phase 3 Study of Fidaxomicin for the Treatment of Clostridium difficile Infection (CDI) Presented at ECCMID
Positive Results from Optimer Pharmaceuticals' Second Phase 3 Study of Fidaxomicin for the Treatment of Clostridium difficile Infection (CDI) Presented at ECCMID
Positive Results from Optimer Pharmaceuticals' Second Phase 3 Study of Fidaxomicin for the Treatment of Clostridium difficile Infection (CDI) Presented at ECCMID
Submitted by
admin
on April 11, 2010 - 11:30am
Source:
Yahoo/PR NewsWire
News Tags:
Optimer
fidaxomicin
Clostridium Difficile
Headline:
Positive Results from Optimer Pharmaceuticals' Second Phase 3 Study of Fidaxomicin for the Treatment of Clostridium difficile Infection (CDI) Presented at ECCMID
Do Not Allow Advertisers to Use My Personal information
